Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?

被引:22
作者
Vanrenterghem, YFC [1 ]
机构
[1] Univ Hosp Gasthuisberg, Dept Nephrol, B-3000 Louvain, Belgium
关键词
D O I
10.1097/00041552-199911000-00003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cyclosporine and tacrolimus are potent inhibitors of the calcineurin-dependent cytokine synthesis in activated lymphocytes. In renal transplant patients tacrolimus is more powerful in preventing severe and refractory rejections, even when compared with the new cyclosporine microemulsion formulation. Both drugs are equally nephrotoxic, but tacrolimus induces less hypertension and less pronounced hyperlipidaemia, Especially in some categories of patients, a higher incidence of de-novo diabetes mellitus is seen with tacrolimus therapy. Curr Opin Nephrol Hypertens 8:669-674. (C) 1999 Lippincott Wiliiams & Wilkins.
引用
收藏
页码:669 / 674
页数:6
相关论文
共 35 条
[1]   Lipoprotein patterns in renal transplant patients:: A comparison between FK 506 and cyclosporine a patients [J].
Claesson, K ;
Mayer, AD ;
Squifflet, JP ;
Grabensee, B ;
Eigler, FW ;
Behrend, M ;
Vanrenterghem, Y ;
van Hooff, J ;
Morales, JM ;
Johnson, RWG ;
Buchholz, B ;
Land, W ;
Forsythe, JLR ;
Neumayer, HH ;
Ericzon, BG ;
Mühlbacher, F .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1292-1294
[2]   Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus [J].
Friemann, S ;
Feuring, E ;
Padberg, W ;
Ernst, W .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1240-1242
[3]   The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival2 [J].
Gjertson, DW ;
Cecka, JM ;
Terasaki, PI .
TRANSPLANTATION, 1995, 60 (12) :1384-1388
[4]   Comparative trial of Prograf (tacrolimus) in combination with azathioprine or mycophenolate mofetil vs. neoral (cyclosporine) with mycophenolate mofetil after kidney transplantation [J].
Gonwa, T ;
Ahsan, N ;
Halloran, P ;
Stegall, M ;
Hardy, M ;
Metzger, R ;
Shield, C ;
Rocher, L ;
Scandling, J ;
Sorense, J ;
Mulloy, L ;
Light, J ;
Corwin, C ;
Danovitch, G ;
Wachs, M ;
Van Veldhuisen, P ;
Salm, K ;
Tolzman, D ;
Fitzsimmons, W .
TRANSPLANTATION, 1999, 67 (07) :S239-S239
[5]   An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs [J].
Hutchinson, IV .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (06) :665-671
[6]  
HUTCHINSON IV, 1999, IN PRESS TRANSPLANT
[7]   Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the US multicenter, randomized, comparative trial [J].
Jensik, SC .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1216-1218
[8]   Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival [J].
Jiang, HS ;
Sakuma, S ;
Fujii, Y ;
Akiyama, Y ;
Ogawa, T ;
Tamura, K ;
Kobayashi, M ;
Fujitsu, T .
TRANSPLANT INTERNATIONAL, 1999, 12 (02) :92-99
[9]   Tacrolimus for rescue of refractory renal allograft rejection [J].
Jordan, ML ;
Naraghi, R ;
Shapiro, R ;
Smith, D ;
Vivas, CA ;
Scantlebury, VP ;
Gritsch, HA ;
McCauley, J ;
Randhawa, P ;
Demetris, AJ ;
McMichael, J ;
Fung, JJ ;
Starzl, TE .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1257-1260
[10]   Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation [J].
Keown, P ;
Niese, D .
KIDNEY INTERNATIONAL, 1998, 54 (03) :938-944